Simultaneous quantitation of intracellular zidovudine and lamivudine triphosphates in human immunodeficiency virus-infected individuals.
Highly active antiretroviral therapy (HAART) is the standard treatment for infection with human immunodeficiency virus (HIV). The most common HAART regimen consists of the combination of at least one protease inhibitor (PI) with two nucleoside reverse transcriptase inhibitors (NRTIs). Contrary to PIs, NRTIs require intracellular activation from the parent compound of their triphosphate moiety to suppress HIV replication. Simultaneous intracellular determination of two NRTI triphosphates is difficult to accomplish due to their relatively small concentrations in peripheral blood mononuclear cells (PBMCs), requiring large amounts of blood from HIV-positive patients. Recently, we described a method to determine intracellular zidovudine triphosphate (ZDV-TP) concentrations in HIV-infected patients by using solid-phase extraction and tandem mass spectrometry. The limit of quantitation (LOQ) for ZDV-TP was 0.10 pmol, and the method was successfully used for the determination of ZDV-TP in HIV-positive patients. In this study, we enhanced the aforementioned method by the simultaneous quantitation of ZDV-TP and lamivudine triphosphate (3TC-TP) in PBMCs from HIV-infected patients. The LOQ for 3TC-TP was 4.0 pmol, with an interassay coefficient of variation and an accuracy of 7 and 12%, respectively. This method was successfully applied to the simultaneous in vivo determination of the ZDV-TP and 3TC-TP pharmacokinetic profiles from HIV-infected patients receiving HAART.
Rodriguez
J F
JF
Department of Biochemistry, School of Medicine, Medical Sciences Campus, University of Puerto Rico, Puerto Rico. j_rodriguez@rcmaxp.upr.clu.edu
Rodriguez
J L
JL
Santana
J
J
García
H
H
Rosario
O
O
D019380:Anti-HIV Agents / Q000097:blood* / Q000627:therapeutic use; D002852:Chromatography, Ion Exchange; D003570:Cytidine Triphosphate / Q000031:analogs & derivatives / Q000097:blood*; D054306:Dideoxynucleotides; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000031:analogs & derivatives / Q000097:blood* / Q000378:metabolism / Q000627:therapeutic use; D012015:Reference Standards; D013942:Thymine Nucleotides / Q000097:blood*; D015215:Zidovudine / Q000031:analogs & derivatives / Q000097:blood* / Q000378:metabolism / Q000627:therapeutic use
D019380:Anti-HIV Agents; D054306:Dideoxynucleotides; D013942:Thymine Nucleotides; C417268:lamivudine triphosphate; D019259:Lamivudine; D015215:Zidovudine; D003570:Cytidine Triphosphate; C052873:zidovudine triphosphate